Here's the Biggest Challenge Biogen Will Face if Its Alzheimer's Drug Is Approved
A crucial decision is days -- or maybe even hours -- away for Biogen (NASDAQ: BIIB). By June 7, the Food and Drug Administration will decide whether to approve the biotech company's controversial Alzheimer's drug candidate. A positive decision seems crucial for Biogen because the company predicts declining sales of its big multiple sclerosis blockbuster and is in need of a new growth driver.
If the FDA gives the nod to the Alzheimer's candidate, aducanumab, it's very likely Biogen shares will soar. More than 6 million Americans suffer from the disease, and treatment options are extremely limited. But Biogen might not get the major revenue boost it's hoping for even if aducanumab wins approval. Let's look at the biggest challenge the company could face.
Image source: Getty Images.
Source Fool.com
